- ROUNDTABLE: Improving patient outcomes, controlling costs with OTCs
- Study from NCPA sheds new light on med synchronization programs
- Reports: Mich. bill would allow marijuana sales in pharmacies
- ROUNDTABLE: Pharmacy’s future in sync with technology
- NACDS, NCPA, GPhA express support for Drug Quality and Security Act
IRVINE, Calif. — Anticipating regulatory approval, MAP Pharmaceuticals and Allergan will collaborate to promote a drug for treating acute migraine to physicians.
The two companies announced the collaboration Monday for Levadex (dihydroergotamine), an inhaled drug. Phase-3 trials for the drug are finished, and MAP plans to submit an approval application for the drug to the Food and Drug Administration in the first half of this year.
If the drug is approved, Allergan and MAP will co-promote the drug to neurologists and pain specialists, and Allergan will use members of its sales force who already have experience promoting Botox for chronic migraine. MAP will be responsible for manufacturing and distribution, receiving an upfront payment of $60 million from Allergan and up to $97 million in milestones. The two companies will share profits.